Uric acid nephrolithiasis appears to increase in prevalence. While a relationship between uric acid stones and low urinary pH has been for long known, additional association with various metabolic conditions and pathophysiological basis has recently been elucidated. Some conditions such as diabetes and metabolic syndrome disease, excessive dietary intake, and increased endogenous uric acid production and/or defect in ammoniagenesis are associated with low urinary pH. In addition, the phenomenon of global warming could result in an increase in areas with greater climate risk for uric acid stone formation. There are three therapeutic steps to be taken for management of uric acid stones: identification of urinary pH profiles, assessment of urinary volume status, and identification of disorders leading to excessive uric acid production. However, the most important factor for uric acid stone formation is acid urinary pH, which is a prerequisite for uric acid precipitation. This article reviews recent insights into the pathophysiology of uric acid stones and their management.
MosesRPaisVMJrUrsinyMet al. Changes in stone composition over two decades: evaluation of over 10,000 stone analyses. Urolithiasis2015; 43: 135–139.
2.
StamatelouKKFrancisMEJonesCAet al. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int2003; 63: 1817–1823.
3.
ScalesCDJrSmithACHanleyJMet al. Prevalence of kidney stones in the United States. Eur Urol2012; 62: 160–165.
4.
KnollTShubertABFahlenkampDet al. Urolithiasis through the ages: data on more than 200,000 urinary stone analyses. J Urol2011; 185: 1304–1311.
5.
Sanchez-MartinFMMillan RodriguezFEsquena FernandezSet al. Incidence and prevalence of published studies about urolithiasis in Spain. A review. Actas Urol Esp2007; 31: 511–520.
6.
Arias FunezFGarcia CuerpoELovaco CastellanosFet al. Epidemiology of urinary lithiasis in our unit. Clinical course in time and predictive factors. Arch Esp Urol2000; 53: 343–347.
7.
CroppiEFerraroPMTaddeiLet al. Prevalence of renal stones in an Italian urban population: a general practice-based study. Urol Res2012; 40: 517–522.
8.
TrinchieriARoveraFNespoliRet al. Clinical observations on 2086 patients with upper urinary tract stone. Arch Ital Urol Androl1996; 68: 251–262.
9.
Arias VegaMRPerula de TorresLACarrasco ValienteJet al. Prevalence of urolithiasis in the 40 to 65 year old Spanish population: the PreLirenE study. Med Clin2016; 146: 525–531.
10.
De Miguel-ElizagaIMartinez-RuizAAviles-PlazaFet al. Kidney stones in a Mediterranean population from the south of Spain. Clin Chem Lab Med2011; 50: 545–548.
11.
GiannossiMLMongelliGTateoFet al. Mineralogical and morphological investigation of kidney stones of a Mediterranean region (Basilicata, Italy). J Xray Sci Technol2012; 20: 175–186.
12.
TrinchieriAMontanariE.Prevalence of renal uric acid stones in the adult. Urolithiasis2017; 45: 553–562.
13.
TaylorENCurhanGC.Body size and 24-hour urine composition. Am J Kidney Dis2006; 48: 905–915.
14.
MaaloufNMCameronMAMoeOWet al. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol2007; 2: 883–888.
15.
DaudonMLacourBJungersP.High prevalence of uric acid calculi in diabetic stone formers. Nephrol Dial Transplant2005; 20: 468–469.
16.
MaaloofNMSakahaeeKParksJHet al. Association of urinary pH with body weight in nephrolithiasis. Kidney Int2004; 65: 1422–1425.
17.
FlegalKMCarrollMDOgdenCLet al. Prevalence and trends in obesity among us adults, 1999–2000. JAMA2002; 288: 1723–1727.
18.
AsplinJR.Obesity and urolithiasis. Adv Chronic Kidney Dis2009; 16: 11–20.
19.
EkeruoWOTanYHYoungMDet al. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol2004; 172: 159–163.
20.
DaudonMLacourBJungersP.Influence of body size on urinary stone composition in men and women. Urol Res2006; 34: 193–199.
21.
PakCYCSakaeeKMoeOWet al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology2003; 61: 523–527.
22.
DaudonMTraxerOConortPet al. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol2006; 17: 2026–2033.
23.
RendinaDDe FilippoPD’EliaGet al. Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence. J Nephrol2014; 27: 371–376.
24.
WestBLukeADurazo-ArvizuRAet al. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988–1994. Am J Kidney Dis2008; 51: 741–747.
25.
MoeOWAbateNSakhaeeK.Pathophysiology of uric acid nephrolithiasis. Endocrinol Metab Clin North Am2002; 31: 895–914.
26.
KennyJSGoldfarbDS.Update on the pathophysiology and management of uric acid renal stones. Curr Rheumatol Rep2010; 12: 125–129.
Alvarez-NemegyeiJMedina-EscobedoMVillanueva-JorgeSet al. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed?J Rheumatol2005; 32: 2189–2191.
FinlaysonBSmithLH.Stability of the first dissociable proton of uric acid. J Chem Eng Data1974; 19: 94–97.
33.
KlinebergJRGoldfingerSFSeegmillerJO.The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med1965; 62: 639–647.
34.
PetersJPVan SlykeKK.Quantitative clinical chemistry, version 1. 2nd ed.Baltimore, MD: Lippincott Williams & Wilkins; 1946, p. 937.
35.
GrossmanMSNugentFW.Urolithiasis as a complication of chronic diarrheal disease. Am J Dig Dis1967; 12: 491–498.
36.
SakhaeeKNigamSSnellPet al. Assessment of the pathogenetic role of physical exercise in renal stone formation. J Clin Endocrinol Metab1987; 65: 974–979.
37.
ReddySTWangCYSakhaeeKet al. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis2002; 40: 265–274.
38.
AbateNChandaliaMCabo-ChanAVet al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int2004; 65: 386–392.
39.
MaaloufNM.Metabolic syndrome and the genesis of uric acid stones. J Ren Nutr2011; 21: 128–131.
40.
PlanteGEDurivageJLemieuxG.Renal excretion of hydrogen in primary gout. Metabolism1968; 17: 377–385.
41.
HennemanPAWallachSDempseyEF.The metabolic defect responsible for uric acid stone formation. J Clin Invest1962; 41: 537–540.
42.
Metcalfe-GibsonAMacCallumPMorrisonRBIet al. Urinary excretion of hydrogen ion in patients with uric acid calculi. Clin Sci1965; 28: 325–342.
FallsWFJr.Comparison of urinary acidification and ammonium excretion in normal and gouty subjects. Metabolism1972; 21: 43–45.
45.
CameronMASakheeK.Uric acid nephrolithiasis. Urol Clin North Am2007; 34: 335–346.
46.
PremingerGM.Pharmacological treatment of uric acid calculi. Urol Clin North Am1987; 14: 335–338.
47.
LowRKStollerML.Uric acid-related nephrolithiasis. Urol Clin North Am1997; 24: 135–138.
48.
SakhaeeKNicarMHillKet al. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salt. Kidney Int1983; 24: 348–352.
49.
FreedSZ.The alternative use of an alkaline salt and acetazolamide in the management of cysteine and uric acid stones. J Urol1973; 113: 96–99.
50.
WelchBJGraybealDMoesOWet al. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis2006; 48: 555–563.
PakCYCSakhaeeKFullerC.Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int1986; 30: 422–426.
53.
CoeFLEvanAWorcesterE.Kidney stone disease. J Clin Invest2005; 115: 2598–2608.
54.
RodmanJS.Prophylaxis of uric acid stones with alternate day doses of alkaline potassium salts. J Urol1991; 145: 97–99.
55.
TungKHTanECFooKT.Chemolysis of uric acid stones. Ann Acad Med Singapore1984; 13: 620–624.
56.
RodmanJS.Intermittent versus continuous alkaline therapy for uric acid stones and ureteral stones of uncertain composition. Urology2002; 60: 378–382.
57.
SeltzerMALowRKMcDonaldMet al. Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol1996; 156: 907–909.
58.
GoodmanJWAsplinJRGoldfarbDS.Effect of two sports drinks on urinary lithogenicity. Urol Res2009; 37: 41–46.
59.
OdvinaC.Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clin J Am Soc Nephrol2006; 1: 1269–1274.
60.
Food and Nutrition Board. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids (Micronutrients). Washington, DC: National Academies Press, 2002, pp. 589–768, http://books.nap.edu/catalog/10490.html
61.
BeckerJWSchumacherHRJrWortmannRLet al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med2005; 353: 2450–2461.
